Ryan Hafner, MD
Physical Medicine & Rehabilitation · Sarasota, FLNPI 1548793326
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Merz Pharmaceuticals, LLC at 52.3% of the total. 2025 is the largest year on record at $72,257, more than ten times the $156 reported in 2020. Among physical medicine & rehabilitation clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 296 payments — averaging $553.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merz Pharmaceuticals, LLC$86K
- Ipsen Biopharmaceuticals, Inc$54K
- Medtronic$17K
- AbbVie$5K
- Pacira Pharmaceuticals Incorporated$1K
- Amgen$207
- plus $1K from 28 others
Across 14 payments — averaging $2554.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merz Pharmaceuticals, LLC$33K
- Pacira Pharmaceuticals Incorporated$3K
What the payments were for
- Consulting fees$39,31024%
- Speaking & faculty fees$81,97950%
- Grants$15,0009%
- Travel & lodging$18,77811%
- Food & beverage$8,6825%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merz Pharmaceuticals, LLC | 138 | $85,582 |
| Ipsen Biopharmaceuticals, Inc | 41 | $53,507 |
| Medtronic | 13 | $16,721 |
| AbbVie | 32 | $4,887 |
| Pacira Pharmaceuticals Incorporated | 19 | $1,427 |
| Amgen(2 entities) | 6 | $207 |
| Merz North America, Inc. | 2 | $156 |
| Argenx US, Inc. | 5 | $152 |
| Merck | 1 | $124 |
| Revance Therapeutics, Inc. | 1 | $122 |
| GE HealthCare | 6 | $101 |
| Biogen | 1 | $93 |
| Saol Therapeutics Inc. | 1 | $76 |
| Lilly USA, LLC | 4 | $63 |
| GRT US Holding, Inc. | 1 | $50 |
| Microtransponder, Inc. | 2 | $44 |
| CSL Behring | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Acadia Pharmaceuticals Inc | 2 | $36 |
| Corium, LLC | 1 | $33 |
| MDD US Operations, LLC | 2 | $33 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Pfizer | 2 | $28 |
| Banner Life Sciences, LLC | 1 | $24 |
| UCB, Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Bioventus LLC | 1 | $18 |
| Smith+Nephew | 1 | $18 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Tanabe Pharma America, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$77,289
- DYSPORT$49,263
- ASCENDA$15,000
- INBRIJA$3,620
- BOTOX$2,780
- Iovera$960
- SYNCHROMED$925
- SYNCHROMEDII$329
- VERQUVO$249
- DAXXIFY$122
- UPLIZNA$114
- INTELLIS ADAPTIVESTIM$110
How this compares
$163,749 in reported general payments places this provider in the 95th percentile of 618 physical medicine & rehabilitation providers in Florida.
See all physical medicine & rehabilitation providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DysportAbobotulinumtoxina | 21 | $50,602 |
| EliquisApixaban | 11 | $6,378 |
| Baclofen | 47 | $1,701 |
| Tizanidine Hcl | 31 | $1,327 |
| Gabapentin | 45 | $744 |
| Enoxaparin Sodium | 11 | $634 |
| Dantrolene Sodium | 12 | $463 |
| Celecoxib | 13 | $409 |
| Atorvastatin Calcium | 30 | $243 |
| Methocarbamol | 15 | $177 |
| Metoprolol Succinate | 15 | $147 |
| Oxycodone Hcl | 15 | $92 |
| Pantoprazole Sodium | 14 | $90 |
| Lisinopril | 11 | $49 |
| Metformin Hcl | 11 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Ipsen Biopharmaceuticals, IncDysport | $53,507 | $50,60221 claims |
| PfizerEliquis | $28 | $6,37811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 618 physical medicine & rehabilitation providers in Florida.
Other physical medicine & rehabilitation in Sarasota
- Anthony GiuffridaFort Lauderdale$271K
- Cassandra ListJacksonville$154K
- Marissa McCarthyTampa$94K
- Jose Medina SanchezTampa$30K
- Alan MillerFernandina Beach$26K
- Anish SoniNaples$25K
- Jose de la TorreWesley Chapel$23K
- Kaivalya DeshpandeMiami$22K
- Ryan RamsookTallahassee$21K
- James AtchisonJacksonville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.